Carterra’s Vega platform expands surface plasmon resonance (SPR) throughput to enable label-free, kinetic and off-target profiling at screening scale, allowing tens of thousands of compounds per day. In an Innovation Spotlight, Carterra executives described Vega’s role in moving SPR from downstream validation into earlier discovery workflows. Vega leverages dense-array SPR to capture on- and off-rates, affinity and specificity metrics at speeds previously reserved for low-throughput, high-information assays. Developers argue this can reduce false positives early, de-risk lead selection and accelerate medicinal chemistry cycles. Early adopters in pharma and biotech reported that integrating SPR kinetics earlier shortened decision times and provided richer structure–activity data. Carterra positions Vega as a complementary data layer to high-throughput biochemical and cellular screens. Lab operations teams should evaluate workflow integration, sample consumption and data pipelines. Investors and discovery chiefs will weigh Vega’s ability to shift cost structures by substituting orthogonal biophysical readouts for downstream attrition mitigation.